Purchase Order 36C24226P0480
Award Date 3/18/26
Potential Completion Date 3/25/26
Potential Value $39K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 2 (VISN 2) awarded a firm fixed-price purchase order to Theracom, L.L.C. for TAKHZYRO 150MG/ML injection in 2ML syringe formulation on February 24, 2026. The contract has a ceiling value of $38,875.02 with an ultimate completion date of March 24, 2026. The award was made without a set-aside designation, reflecting full and open competition. Theracom, a Kentucky-based pharmaceutical specialty distributor headquartered in...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5) awarded a firm fixed-price purchase order to Theracom, L.L.C. for $38,097.52 for the supply of TAKHZYRO 150 MG, a specialized biologic pharmaceutical therapy. The contract was awarded on March 2, 2026, with an ultimate completion date of March 4, 2026, and no set-aside designation was utilized. Theracom, headquartered in Shepherdsville, Kentucky and operating from its Brooks, Kentucky facility, is a specialized...
- The Department of Veterans Affairs, through Veterans Integrated Service Network 5 (VISN 5), awarded a firm fixed-price purchase order valued at $38,097.52 to Theracom, L.L.C. for the supply of TAKHZYRO 150 MG, a specialized biologic pharmaceutical therapy. The award was made on March 24, 2026, with an ultimate completion date of March 27, 2026, and does not include a set-aside designation. Performance will occur at Theracom's facility in Brooks, Kentucky. Theracom is a pharmaceutical procurement...
- Theracom, L.L.C., a child entity, has been awarded a firm fixed price purchase order by the Veterans Integrated Service Network 2 (VISN 2), a civilian component of the Department of Veterans Affairs, for the supply of TAKHZYRO 150MG. The contract, issued on December 1, 2025, carries a ceiling value of $75,478.12 and is scheduled for ultimate completion by December 30, 2025. The contract was awarded without a set-aside designation and will be performed in Brooks, Kentucky. TAKHZYRO...
- Theracom, L.L.C., a child entity, was awarded a firm fixed-price purchase order by Veterans Integrated Service Network 2 on October 20, 2025, for the supply of TAKHZYRO (pegtanercept) 150MG/ML injection in a 2ML syringe formulation. This is a pharmaceutical supply contract with a ceiling value of approximately $37.7K, with an ultimate completion date of November 20, 2025. The contract was awarded without a set-aside designation, and the place of performance is listed as Brooks, Kentucky. This...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awards Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price contract to supply TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE with a quantity of 2. The contract is issued against Takeda Pharmaceuticals America Inc.'s existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking place in Lexington, Massachusetts. No...
- <p>This federal contract award is for the procurement of TAKHYZRO medication for patient use. The contract was awarded to Theracom, L.L.C., a for-profit limited liability company, on September 10, 2025. The contract has a firm fixed price of $37,739.06 and a completion date of October 31, 2025. The funding agency is the Veterans Integrated Service Network 2, a civilian agency. The contract does not have a set-aside designation.</p>
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order against the company's GSA Schedule contract for Pharmaceuticals and Drugs. The delivery order is for TAKHZYRO 150MG/ML SYRINGE 2ML SYRINGE (2) to be supplied to Veterans Integrated Service Network 9, with performance taking place in Lexington, Massachusetts from September 6-7, 2023. As the prime contractor, Takeda Pharmaceuticals America...